Bicara Therapeutics (BCAX) Stock Price, News & Analysis

Company Overview

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: $11.09 to $11.95
• 50-Day Range: $9.37 to $16.55
• 52-Week Range: $8.91 to $28.09
• Volume: 292,742 shs
• Average Volume: 470,382 shs
• Market Capitalization: $624.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $36.50
• Consensus Rating: Buy

BCAX Stock Analysis - Frequently Asked Questions

How have BCAX shares performed this year?

Bicara Therapeutics' stock was trading at $17.42 at the start of the year. Since then, BCAX shares have decreased by 34.3% and is now trading at $11.45.
View the best growth stocks for 2025 here.

How were Bicara Therapeutics' earnings last quarter?

Bicara Therapeutics Inc. (NASDAQ:BCAX) released its quarterly earnings data on Thursday, March, 27th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.08.

When did Bicara Therapeutics IPO?

Bicara Therapeutics (BCAX) raised $315 million in an initial public offering on Friday, September 13th 2024. The company issued 17,500,000 shares at a price of $18.00 per share.

When did Bicara Therapeutics' lock-up period expire?

Bicara Therapeutics' lock-up period expired on Wednesday, March 12th. Bicara Therapeutics had issued 17,500,000 shares in its initial public offering on September 13th. The total size of the offering was $315,000,000 based on an initial share price of $18.00. Since the end of Bicara Therapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Who are Bicara Therapeutics' major shareholders?

Top institutional shareholders of Bicara Therapeutics include Rhumbline Advisers (0.04%), GAMMA Investing LLC (0.01%) and Avanza Fonder AB (0.01%).
View institutional ownership trends.

How do I buy shares of Bicara Therapeutics?

Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 3/27/2025
• Today: 4/15/2025
• Next Earnings (Estimated): 6/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCAX
• Previous Symbol: NASDAQ:BCAX
• CIK: 2023658
• Web: www.bicara.com
• Phone: (617) 468-4219
• Fax: N/A
• Employees: 32
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $36.50
• High Stock Price Target: $48.00
• Low Stock Price Target: $13.01
• Potential Upside/Downside: +218.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 54,523,000
• Free Float: N/A
• Market Cap: $624.29 million
• Optionable: N/A
• Beta: N/A